A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

Pneumagen has announced the publication of phase 2 data showing its antiviral therapy, Neumifil, significantly reduced ...

Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting ...

Long before chewing gum came in shiny foil wrappers with watermelon flavors and whitening promises, our ancestors were ...

Galapagos announces leadership transition. European biotechnology company Galapagos completed a significant leadership ...

As respiratory illnesses like COVID-19, influenza, and Mycoplasma pneumonia continue to spread, the need for safe, non-pharmaceutical prevention options is growing. South Korea-based biotech firm LUCA ...

COVID is still with us, and there will be other pandemics. It’s critical that we don’t forget the lessons we’ve learned.” ...

The Mpox virus can also infect the human brain and damage brain cells. In view of the recent worldwide increase in Mpox cases ...

The disease is often mild, with flu-like symptoms and a rash ... The research team also tested the effect of the antiviral drug Tecovirimat. The treatment was able to significantly reduce the viral ...

The University of Minnesota is stepping up efforts to identify biological threats that could trigger an epidemic, launching ...